This Article Full Text Full Text (PDF) All Versions of this Article: 110/11/1477    most recent 01.CIR.0000141733.55236.9Dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Plante, E. Articles by Couet, J. Search for Related Content PubMed PubMed Citation Articles by Plante, E. Articles by Couet, J. Related Collections Remodeling Animal models of human disease Hypertrophy Valvular heart disease Echocardiography

(Circulation. 2004;110:1477-1483.)
© 2004 American Heart Association, Inc.

Original Articles

Effectiveness of ß-Blockade in Experimental Chronic Aortic Regurgitation

Eric Plante, MSc; Dominic Lachance, BSc; Martin Gaudreau, MSc; Marie-Claude Drolet, MSc; Élise Roussel, MSc; Marie Arsenault, MD; Jacques Couet, PhD

From the Groupe de Recherche sur les Valvulopathies, Centre de Recherche Hôpital Laval, Institut de Cardiologie de Québec, Université Laval, Quebec, Canada.

Correspondence to Marie Arsenault, MD, Institut de Cardiologie de Québec, 2725 chemin Sainte-Foy, Sainte-Foy, Quebec, Canada, G1V 4G5. E-mail marie.arsenault{at}crhl.ulaval.ca

Received February 11, 2004; de novo received March 24, 2004; revision received May 26, 2004; accepted June 3, 2004.

Background— Past studies have suggested that the adrenergic system becomes abnormally activated in chronic volume overload, such as in severe aortic valve regurgitation (AR). However, the effectiveness of agents directed against this adrenergic activation has never been adequately tested in chronic AR. We therefore tested the effects of metoprolol treatment on the left ventricular (LV) function and remodeling in severe chronic AR in rats.

Methods and Results— Severe AR was created in adult male Wistar rats by retrograde puncture of the aortic leaflets under echocardiographic guidance. Two weeks later, some animals received metoprolol treatment (25 mg/kg) orally for 24 weeks, and some were left untreated. LV dimensions, ejection fraction, and filling parameters were evaluated by echocardiography. Hearts were harvested at 1, 2, 14, and 180 days for the evaluation of hypertrophy, ß-adrenergic receptor status, and extracellular matrix remodeling. We found that metoprolol treatment prevented LV dilatation and preserved the ejection fraction and filling parameters compared with untreated animals. Metoprolol increased the expression of ß₁-adrenoreceptor mRNA and reduced G protein receptor kinase 2 levels. Collagen I and III mRNA levels were reduced. Cardiac myocyte hypertrophy was also prevented.

Conclusions— In our experimental model of severe AR, metoprolol treatment had a significant beneficial global effect on LV remodeling and function. These results suggest that the adrenergic system is important in the development of volume-overload cardiomyopathy in AR and that adrenergic-blocking agents may play a role in the treatment of this disease.

Key Words: valve, aortic, insufficiency • echocardiography • regurgitation • receptors, adrenergic, beta

This article has been cited by other articles:

				D. Lachance, E. Plante, A.-A. Bouchard-Thomassin, S. Champetier, E. Roussel, M.-C. Drolet, M. Arsenault, and J. Couet Moderate Exercise Training Improves Survival and Ventricular Remodeling in an Animal Model of Left Ventricular Volume Overload Circ Heart Fail, September 1, 2009; 2(5): 437 - 445. [Abstract] [Full Text] [PDF]

				Y. Lu, Y. Zhang, H. Shan, Z. Pan, X. Li, B. Li, C. Xu, B. Zhang, F. Zhang, D. Dong, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection Cardiovasc Res, July 31, 2009; (2009) cvp232v2. [Abstract] [Full Text] [PDF]

				U. Sampat, P. Varadarajan, R. Turk, A. Kamath, S. Khandhar, and R. G. Pai Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation results from a cohort of 756 patients. J. Am. Coll. Cardiol., July 28, 2009; 54(5): 452 - 457. [Abstract] [Full Text] [PDF]

				U. Elkayam Beta-blockers in the treatment of aortic regurgitation a new opportunity? J. Am. Coll. Cardiol., July 28, 2009; 54(5): 458 - 459. [Full Text] [PDF]

				S. Champetier, A. Bojmehrani, J. Beaudoin, D. Lachance, E. Plante, E. Roussel, J. Couet, and M. Arsenault Gene profiling of left ventricle eccentric hypertrophy in aortic regurgitation in rats: rationale for targeting the {beta}-adrenergic and renin-angiotensin systems Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H669 - H677. [Abstract] [Full Text] [PDF]

				E. Plante, D. Lachance, J. Beaudoin, S. Champetier, E. Roussel, M. Arsenault, and J. Couet Comparative Study of Vasodilators in an Animal Model of Chronic Volume Overload Caused by Severe Aortic Regurgitation Circ Heart Fail, January 1, 2009; 2(1): 25 - 32. [Abstract] [Full Text] [PDF]

				E. Plante, D. Lachance, S. Champetier, M.-C. Drolet, E. Roussel, M. Arsenault, and J. Couet Benefits of long-term {beta}-blockade in experimental chronic aortic regurgitation Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1888 - H1895. [Abstract] [Full Text] [PDF]

				S. H. Rahimtoola The Year in Valvular Heart Disease J. Am. Coll. Cardiol., January 17, 2006; 47(2): 427 - 439. [Full Text] [PDF]